Skip Navigation

This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Search for citing articles in:
ISI Web of Science (11)
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Byrne, C. D
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Byrne, C. D
Related Collections
Right arrow Diabetes
Right arrow Endocrinology
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

British Medical Bulletin 60:153-171 (2001)
© 2001 Oxford University Press

Programming other hormones that affect insulin

Type 2 diabetes

Christopher D Byrne

Endocrinology and Metabolism Unit, School of Medicine, University of Southampton, Southampton, UK

The metabolic syndrome is associated with a marked increase in risk of type 2 diabetes and atherosclerotic vascular disease (AVD). The mechanism responsible for the metabolic syndrome is uncertain, but recent evidence suggests that a combination of low birth weight and adult obesity is associated with a markedly increased prevalence. Insulin resistance is the cardinal feature of the metabolic syndrome. Several hormones, have modes of action that either potentiate or reduce the biological actions of insulin and, therefore, attenuate or induce insulin resistance. Since insulin action may be modified, these hormones potentially contribute to the pathogenesis of the metabolic syndrome.

The purpose of this review is to discuss programming of hormones that modulate insulin action. The review focuses on two major endocrine pathways: (i) glucocorticoid hormone action; and (ii) the growth hormone (GH)-insulin-like growth factor (IGF-1) axis, and discusses mechanisms linking abnormal activity of these pathways with reduced early growth, adult obesity and the metabolic syndrome


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
 Proc R Soc BHome page
E. H Chin, O. P Love, J. J Verspoor, T. D Williams, K. Rowley, and G. Burness
Juveniles exposed to embryonic corticosterone have enhanced flight performance
Proc R Soc B, February 7, 2009; 276(1656): 499 - 505.
[Abstract] [Full Text] [PDF]

Home page
 J Am Board Fam MedHome page
K. E. Innes, C. Bourguignon, and A. G. Taylor
Risk Indices Associated with the Insulin Resistance Syndrome, Cardiovascular Disease, and Possible Protection with Yoga: A Systematic Review
J Am Board Fam Med, November 1, 2005; 18(6): 491 - 519.
[Abstract] [Full Text] [PDF]

Home page
 Mol. Endocrinol.Home page
M. Bazuine, F. Carlotti, R. S. J. Tafrechi, R. C. Hoeben, and J. A. Maassen
Mitogen-Activated Protein Kinase (MAPK) Phosphatase-1 and -4 Attenuate p38 MAPK during Dexamethasone-Induced Insulin Resistance in 3T3-L1 Adipocytes
Mol. Endocrinol., July 1, 2004; 18(7): 1697 - 1707.
[Abstract] [Full Text] [PDF]

Home page
 Biol. Reprod.Home page
I. Koukoulas, J. Risvanis, R. Douglas-Denton, L. M. Burrell, K. M. Moritz, and E. M. Wintour
Vasopressin Receptor Expression in the Placenta
Biol Reprod, August 1, 2003; 69(2): 679 - 686.
[Abstract] [Full Text] [PDF]


Disclaimer: Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.